TARCC
Targeting alpha-particle emitting radionuclides to combat cancer
| Coordinatore | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
| Nazionalità Coordinatore | France [FR] |
| Sito del progetto | http://www.tarcc.org/ |
| Totale costo | 4˙112˙800 € |
| EC contributo | 3˙000˙000 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-A |
| Funding Scheme | CP-FP |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-01-01 - 2011-06-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | coordinator | 0.00 |
| 2 |
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Organization address
address: Rue Michel -Ange 3 contact info |
FR (PARIS) | participant | 0.00 |
| 3 |
GOETEBORGS UNIVERSITET
Organization address
address: VASAPARKEN contact info |
SE (GOETEBORG) | participant | 0.00 |
| 4 |
INSERM - TRANSFERT SA
Organization address
address: Rue Watt 7 contact info |
FR (PARIS) | participant | 0.00 |
| 5 |
ION BEAM APPLICATIONS SA
Organization address
address: Chemin du Cyclotron, 3 contact info |
BE (LOUVAIN LA NEUVE) | participant | 0.00 |
| 6 |
JRC -JOINT RESEARCH CENTRE- EUROPEAN COMMISSION
Organization address
address: Rue de la Loi 200 contact info |
BE (BRUSSELS) | participant | 0.00 |
| 7 |
KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN
Organization address
address: ISMANINGER STRASSE 22 contact info |
DE (MUENCHEN) | participant | 0.00 |
| 8 |
MEDIZINISCHE HOCHSCHULE HANNOVER
Organization address
address: Carl-Neuberg-Strasse 1 contact info |
DE (HANNOVER) | participant | 0.00 |
| 9 |
UNIVERSITAETSKLINIKUM FREIBURG
Organization address
address: HUGSTETTER STRASSE 49 contact info |
DE (FREIBURG) | participant | 0.00 |
| 10 |
UNIVERSITAETSSPITAL BASEL
Organization address
address: HEBELSTRASSE 32 contact info |
CH (BASEL) | participant | 0.00 |
| 11 |
UNIVERZITETNI KLINICNI CENTER LJUBLJANA
Organization address
address: ZALOSKA CESTA 002 contact info |
SI (LJUBLJANA) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'This project aims at improving drug delivery to cancer cells by developing targeted radiotherapy with alpha-emitting radionuclides. Alpha particles emitted by radionuclides have short tracks (about 100 microns) in body tissues. As a result, they should be most appropriate to treat small-size tumours and isolated cancer cells. This project proposes the development of improved vectors and targeting technology based on specific targeting agents (recombinant antibody fragments and synthetic peptides), pretargeting approaches and nano-colloids especially designed to deliver alpha-emitting radionuclides to cancer cells after local or systemic administration. The concept of in situ generator, that allows the use of longer half-life parents of alpha-emitting radionuclides will be developed. Several approaches to prevent the release of radionuclides after parent isotope disintegration, including encapsulation in nano-colloids, are proposed. Improved targeting methods will be tested in animal models of small-size tumours and associated dosimetry (including micro-dosimetry) and toxicity studies will be performed. The final goal of the project will be to propose one or several new products for targeted delivery of alpha-emitting radionuclides for clinical development.'
Introduzione (Teaser)
European researchers wished to address the challenge of cancer therapy by developing pharmaceuticals coupled to alpha-emitting radionuclides. The TARCC project's proposed approach envisioned site-specific tumour eradication without toxicity to healthy tissues.